Abbott Laboratories (NYSE:ABT) Shares Sold by Oxler Private Wealth LLC

Oxler Private Wealth LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 58.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,397 shares of the healthcare product maker’s stock after selling 10,340 shares during the quarter. Abbott Laboratories accounts for approximately 0.7% of Oxler Private Wealth LLC’s holdings, making the stock its 27th largest position. Oxler Private Wealth LLC’s holdings in Abbott Laboratories were worth $814,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Perigon Wealth Management LLC boosted its position in Abbott Laboratories by 5.2% during the 4th quarter. Perigon Wealth Management LLC now owns 47,080 shares of the healthcare product maker’s stock valued at $5,182,000 after purchasing an additional 2,317 shares during the period. Boston Partners raised its stake in Abbott Laboratories by 634.6% during the 3rd quarter. Boston Partners now owns 29,758 shares of the healthcare product maker’s stock valued at $2,882,000 after acquiring an additional 25,707 shares in the last quarter. VisionPoint Advisory Group LLC raised its stake in Abbott Laboratories by 7.4% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 3,106 shares of the healthcare product maker’s stock valued at $301,000 after acquiring an additional 215 shares in the last quarter. Gradient Investments LLC raised its stake in Abbott Laboratories by 4.7% during the 4th quarter. Gradient Investments LLC now owns 257,508 shares of the healthcare product maker’s stock valued at $28,344,000 after acquiring an additional 11,508 shares in the last quarter. Finally, BKM Wealth Management LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at $2,111,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $1.86 during mid-day trading on Wednesday, reaching $104.82. The company had a trading volume of 5,932,815 shares, compared to its average volume of 5,649,579. The company has a current ratio of 1.60, a quick ratio of 1.11 and a debt-to-equity ratio of 0.32. The stock has a market cap of $182.35 billion, a PE ratio of 32.64, a P/E/G ratio of 2.48 and a beta of 0.76. The company has a 50-day moving average price of $108.89 and a two-hundred day moving average price of $109.54. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The business had revenue of $9.96 billion for the quarter, compared to the consensus estimate of $9.88 billion. During the same quarter in the previous year, the company posted $1.03 earnings per share. Abbott Laboratories’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, equities analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Insider Activity

In other news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 22,852 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $106.25, for a total value of $2,428,025.00. Following the transaction, the executive vice president now owns 61,462 shares in the company, valued at $6,530,337.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,884 shares of company stock worth $5,153,916. 0.47% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Royal Bank of Canada dropped their price objective on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Raymond James reissued a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research note on Wednesday, April 24th. Citigroup dropped their price objective on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating on the stock in a research note on Wednesday. Evercore ISI boosted their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Finally, Barclays dropped their price objective on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, April 22nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $120.60.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.